Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study on the anti-tumoral effect of cannabis oil in advanced untreatable hepatocellular carcinoma
2018-004505-34Phase 2Active
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Transvamix in hepatocellular carcinoma (HCC), sponsored by University Medical Center Groningen. Primary endpoint: Primary anti-tumor effect endpoint. Started Oct 2020; status: active.
02
Drugs
Transvamix
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2018-004505-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004505-34.